Knockdown of HIPK2 Attenuates Angiotensin II–Induced Cardiac Fibrosis in Cardiac Fibroblasts

Feng Xu,Bingbing Mao,Yan Li,Yang Zhao
DOI: https://doi.org/10.1097/fjc.0000000000001292
IF: 3.271
2022-07-13
Journal of Cardiovascular Pharmacology
Abstract:Homeodomain-interacting protein kinase-2 (HIPK2), a member of an evolutionary conserved family of serine/threonine kinases, has been observed to be involved in the pathogenesis of fibrotic diseases. However, its role in cardiac fibrosis remains unclear. In this study, we assessed the effect of HIPK2 on cardiac fibroblasts (CFs) in response to angiotensin II (Ang II) stimulation. The results indicated that HIPK2 expression was significantly increased in Ang II–induced CFs in a dose-dependent manner. Then, HIPK2 was knocked down in CFs to evaluate the roles of HIPK2. Knockdown of HIPK2 suppressed cell proliferation and migration in Ang II–induced CFs. The Ang II–caused increase in expression of α-smooth muscle actin, a hallmark of myofibroblast differentiation, was decreased by knockdown of HIPK2. HIPK2 knockdown also reduced extracellular matrix production including type I collagen and connective tissue growth factor. Furthermore, knockdown of HIPK2 blocked the activation of TGF-β1/Smad pathway in Ang II–induced CFs. These data suggested that HIPK2 knockdown prevented the Ang II–induced activation of CFs through inhibiting TGF-β1/Smad pathway , indicating HIPK2 might be an antifibrosis target for the treatment of cardiac fibrosis.
pharmacology & pharmacy,cardiac & cardiovascular systems
What problem does this paper attempt to address?